Serono drug wins nod in U.S.
Serno SA won its bid to sell its multiple-sclerosis drug Rebif in the U.S. after the Food and Drug Administration decided that patients will benefit more from the thrice-weekly dosage Serono drug
Serno SA won its bid to sell its multiple-sclerosis drug Rebif in the U.S. after the Food and Drug Administration decided that patients will benefit more from the thrice-weekly dosage Serono drug